Page last updated: 2024-09-05

sorafenib and stilbenes

sorafenib has been researched along with stilbenes in 4 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(stilbenes)
Trials
(stilbenes)
Recent Studies (post-2010) (stilbenes)
6,5207305,25113,9352457,836

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Ahn, KS; Baek, SH; Kim, C; Shim, BS; Um, JY1
Bennett, LL; Mondal, A1
Chen, X; Liu, Y; Liu, Z; Ma, S; Sakurai, K; Song, W; Tang, Z; Wang, G; Wang, Y; Yu, H; Zhang, D1
Chen, J; He, ML; Huo, X; Wang, C; Zhao, T1

Other Studies

4 other study(ies) available for sorafenib and stilbenes

ArticleYear
Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPĪµ and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.
    BMC nephrology, 2016, Feb-25, Volume: 17

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Humans; Kidney Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Receptor-Like Protein Tyrosine Phosphatases, Class 4; Resveratrol; S Phase Cell Cycle Checkpoints; Signal Transduction; Sorafenib; STAT3 Transcription Factor; STAT5 Transcription Factor; Stilbenes

2016
Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2016, Volume: 84

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Humans; MCF-7 Cells; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Resveratrol; Sorafenib; Stilbenes; Treatment Outcome

2016
Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
    Acta biomaterialia, 2019, 07-01, Volume: 92

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Survival; Human Umbilical Vein Endothelial Cells; Humans; Ki-67 Antigen; Liver Neoplasms; Male; Mice, Inbred BALB C; Nanoparticles; Platelet Endothelial Cell Adhesion Molecule-1; Sorafenib; Stilbenes; Treatment Outcome; Vascular Endothelial Growth Factor A

2019
Pterostilbene enhances sorafenib's anticancer effects on gastric adenocarcinoma.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:21

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Death; Cell Line, Tumor; Cell Shape; Cell Survival; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Male; Mice, Inbred BALB C; Mice, Nude; Sorafenib; Stilbenes; Stomach Neoplasms; Xenograft Model Antitumor Assays

2020